Development and Interventions on Vaccines and Complications of Coronavirus
Keywords:
Coronavirus (COVID-19) (C19), Complication of COVID-19 (CCV), Adenovirus vector (VVnr), Nucleic acid (RNA), Protein subunit (PS)Abstract
The advent of coronavirus disease has prompted the production of a COVID-19 vaccine. The COVID-19 vaccines, which over 12.7 billion doses worldwide, have been reported to have some complications. Out of the various COVID-19 vaccines, the three most common were studied to analyze their complications. The objectives of the research were (i) evaluation and systematic review of articles based on COVID-19 vaccines, (ii) assessment of complications of variants of COVID-19 vaccines, and (iii) intervention on complications of COVID-19 vaccines from different studies. Adenovirus vector, nucleic acid (mRNA), and protein subunit COVID-19 vaccines complications were assessed and studied using related articles. A systematic review was used to synthesize qualitative findings on COVID-19 vaccine complications. Seventy-five (75) articles were identified and screened from Google, PubMed, Web of Science, and Embase; only 26 articles met the inclusion criteria and were used for the qualitative synthesis. The qualitative findings on COVID-19 vaccine complications were neurological, cerebrovascular, cardiovascular, systemic, and local adverse events.
References
G. Staff, "There are four types of COVID-19 vaccines: here is how they work," ed, 2020.
E. Bolletta et al., "Uveitis and other ocular complications following COVID-19 vaccination," Journal of clinical medicine, vol. 10, no. 24, p. 5960, 2021.
M. De Michele et al., "Cerebrovascular complications of COVID-19 and COVID-19 vaccination," Circulation Research, vol. 130, no. 8, pp. 1187-1203, 2022.
A. L. Goss, R. D. Samudralwar, R. R. Das, and A. Nath, "ANA investigates: neurological complications of COVID?19 vaccines," Annals of neurology, vol. 89, no. 5, p. 856, 2021.
O. H. I. Chou et al., "COVID-19 vaccination and carditis in children and adolescents: A systematic review and meta-analysis," Clinical Research in Cardiology, vol. 111, no. 10, pp. 1161-1173, 2022.
H. Ritchie et al., "Coronavirus pandemic (COVID-19)," Our world in data, 2020.
E. Mathieu et al., "A global database of COVID-19 vaccinations," Nature human behaviour, vol. 5, no. 7, pp. 947-953, 2021.
H. Wang, B. Yu, X. Chen, and H. Yan, "Global pattern and determinants of coronavirus disease 2019 (COVID-19) vaccine coverage and progression: a global ecological study," Global Health Journal, vol. 7, no. 1, pp. 18-23, 2023.
WHO, "COVID-19 vaccine tracker and landscape," ed, 2023.
S. Waheed, A. Bayas, F. Hindi, Z. Rizvi, and P. S. Espinosa, "Neurological complications of COVID-19: Guillain-Barre syndrome following Pfizer COVID-19 vaccine," Cureus, vol. 13, no. 2, 2021.
M. Patone et al., "Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection," Nature medicine, vol. 27, no. 12, pp. 2144-2153, 2021.
A. Fazlollahi et al., "Cardiac complications following mRNA COVID?19 vaccines: A systematic review of case reports and case series," Reviews in medical virology, vol. 32, no. 4, p. e2318, 2022.
R. Liu, J. Pan, C. Zhang, and X. Sun, "Cardiovascular complications of COVID-19 vaccines," Frontiers in Cardiovascular Medicine, vol. 9, 2022.
WHO. Coronavirus disease (COVID-19)-Strategy and planning [Online] Available: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/strategies-and-plans
C. Novel, "The epidemiological attributes of a flare-up of 2019 novel Covid sicknesses (Coronavirus) in china," Zhonghualiuxingbingxuezazhi= Zhonghualiuxingbingxuezazhi, vol. 41, no. 2, p. 145, 2020.
C. Bulut and Y. Kato, "Epidemiology of COVID-19," Turkish journal of medical sciences, vol. 50, no. 9, pp. 563-570, 2020.
S. D. Chowdhury and A. M. Oommen, "Epidemiology of COVID-19," Journal of digestive endoscopy, vol. 11, no. 01, pp. 03-07, 2020.
D. Ndwandwe and C. S. Wiysonge, "COVID-19 vaccines," Current opinion in immunology, vol. 71, pp. 111-116, 2021.
O. J. Watson, G. Barnsley, J. Toor, A. B. Hogan, P. Winskill, and A. C. Ghani, "Global impact of the first year of COVID-19 vaccination: a mathematical modelling study," The Lancet Infectious Diseases, vol. 22, no. 9, pp. 1293-1302, 2022.
A. Mullard, "How COVID vaccines are being divvied up around the world," Nature, vol. 30, no. 10.1038, 2020.
N. Chauhan, B. Manjunath, V. Yadav, A. Kumar, B. Sabbarwal, and J. S. Kumar, "COVID?19 vaccine development in India during Janaury 2021?December 2021: A narrative review," Saudi J Med, vol. 7, no. 2, pp. 118-126, 2022.
H. M. Scobie et al., "Monitoring incidence of COVID-19 cases, hospitalizations, and deaths, by vaccination status—13 US jurisdictions, April 4–July 17, 2021," Morbidity and Mortality Weekly Report, vol. 70, no. 37, p. 1284, 2021.
E. Lamptey, "Post-vaccination COVID-19 deaths: a review of available evidence and recommendations for the global population," Clinical and Experimental Vaccine Research, vol. 10, no. 3, p. 264, 2021.
C. L. Jackson, J. B. Ward, D. A. Johnson, M. Sims, J. Wilson, and S. Redline, "Concordance between self-reported and actigraphy-assessed sleep duration among African-American adults: findings from the Jackson Heart Sleep Study," Sleep, vol. 43, no. 3, p. zsz246, 2020.
H. Ledford, "News in focus," Nature, vol. 592, p. 495, 2021.
D. McGonagle, G. De Marco, and C. Bridgewood, "Mechanisms of immunothrombosis in vaccine-induced thrombotic thrombocytopenia (VITT) compared to natural SARS-CoV-2 infection," Journal of autoimmunity, vol. 121, p. 102662, 2021.
P. C. Fragkou and D. Dimopoulou, "Serious complications of COVID-19 vaccines: A mini-review," Metabolism open, vol. 12, p. 100145, 2021.
A. Oudjedi, A. Allali, A. Bekli, M. Lounis, H. Ben Saad, and M. Boukoufa, "Reported COVID-19 vaccines side effects among Algerian athletes: a comparison between inactivated virus, adenoviral vector, and mRNA COVID-19 vaccines," The Physician and Sportsmedicine, pp. 1-13, 2023.
S. Aghabaklou, S.-M. Razavi, P. Mohammadi, S. Gholamin, and A. Mowla, "Cerebral coagulation complications following COVID-19 adenoviral vector vaccines: a systematic review," Journal of Neurology Research, vol. 11, no. 5, p. 69, 2021.
A. Greinacher, T. Thiele, T. E. Warkentin, K. Weisser, P. A. Kyrle, and S. Eichinger, "Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination," New England Journal of Medicine, vol. 384, no. 22, pp. 2092-2101, 2021.
R. Hosseini and N. Askari, "A review of neurological side effects of COVID-19 vaccination," European Journal of Medical Research, vol. 28, no. 1, pp. 1-8, 2023.
G. Kroumpouzos, M. E. Paroikaki, S. Yumeen, S. Bhargava, and E. Mylonakis, "Cutaneous complications of mRNA and AZD1222 COVID-19 vaccines: a worldwide review," Microorganisms, vol. 10, no. 3, p. 624, 2022.
S. V. Malayala, G. Mohan, D. Vasireddy, and P. Atluri, "Purpuric rash and thrombocytopenia after the mRNA-1273 (Moderna) COVID-19 vaccine," Cureus, vol. 13, no. 3, 2021.
H. Maayan et al., "Acquired thrombotic thrombocytopenic purpura: a rare disease associated with BNT162b2 vaccine," Journal of Thrombosis and Haemostasis, vol. 19, no. 9, pp. 2314-2317, 2021.
O. Dadras et al., "Safety and adverse events related to inactivated COVID-19 vaccines and Novavax; a systematic review," Archives of Academic Emergency Medicine, vol. 10, no. 1, 2022.
S. Kim et al., "Safety surveillance of the NVX-CoV2373 COVID-19 vaccine among Koreans aged 18 years and over," Vaccine, 2023.
F. Yasmin et al., "Adverse events following COVID?19 mRNA vaccines: A systematic review of cardiovascular complication, thrombosis, and thrombocytopenia," Immunity, inflammation and disease, vol. 11, no. 3, p. e807, 2023.
Q. Li and J. Wu, "The Focused Analysis of COVID-19 RNA-based vaccines," Highlights in Science, Engineering and Technology, vol. 36, pp. 866-870, 2023.
H. Y. Kim et al., "A case report for acute myopericarditis after NVX-CoV2373 (Novavax®) COVID-19 vaccination," J Korean Med Sci, vol. 37, no. 34, p. e265, 2022.
E. Underwood et al., "Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine," Expert Review of Vaccines, no. just-accepted, 2023.
A. Bidari et al., "Immune thrombocytopenic purpura secondary to COVID?19 vaccination: A systematic review," European Journal of Haematology, vol. 110, no. 4, pp. 335-353, 2023.
M. Lounis et al., "Side effects of COVID-19 inactivated virus vs. adenoviral vector vaccines: experience of Algerian healthcare workers," Frontiers in public health, vol. 10, 2022.
C. Jacob-Dolan and D. H. Barouch, "COVID-19 vaccines: adenoviral vectors," Annual review of medicine, vol. 73, pp. 41-54, 2022.
Z. A. Abdulla, S. M. Al-Bashir, N. S. Al-Salih, A. A. Aldamen, and M. Z. Abdulazeez, "A summary of the SARS-CoV-2 vaccines and technologies available or under development," Pathogens, vol. 10, no. 7, p. 788, 2021.
J. L. Andresen and O. S. Fenton, "Nucleic acid delivery and nanoparticle design for COVID vaccines," Mrs Bulletin, pp. 1-8, 2021.
E. Twentyman et al., "Interim Recommendation of the Advisory Committee on Immunization Practices for Use of the Novavax COVID-19 Vaccine in Persons Aged? 18 years—United States, July 2022," Morbidity and Mortality Weekly Report, vol. 71, no. 31, p. 988, 2022.
I. P. Trougakos et al., "Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis," Trends in Molecular Medicine, 2022.
K. Guetl, R. B. Raggam, and T. Gary, "Thrombotic Complications after COVID-19 Vaccination: Diagnosis and Treatment Options," Biomedicines, vol. 10, no. 6, p. 1246, 2022.
L. Dai et al., "A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS," Cell, vol. 182, no. 3, pp. 722-733. e11, 2020.
F. Sakurai, M. Tachibana, and H. Mizuguchi, "Adenovirus vector-based vaccine for infectious diseases," Drug Metabolism and Pharmacokinetics, vol. 42, p. 100432, 2022.
H. M. El Sahly et al., "Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase," New England Journal of Medicine, vol. 385, no. 19, pp. 1774-1785, 2021.
WHO. "Cardiovascular diseases." World Health Organization. https://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1 (accessed August 2, 2023).
E. J. Anderson et al., "Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults," New England Journal of Medicine, vol. 383, no. 25, pp. 2427-2438, 2020.
E. Twentyman et al., "Interim Recommendation of the Advisory Committee on Immunization Practices for Use of the Novavax COVID-19 Vaccine in Persons Aged ?18 years - United States, July 2022," (in eng), MMWR Morb Mortal Wkly Rep, vol. 71, no. 31, pp. 988-992, Aug 5 2022, doi: 10.15585/mmwr.mm7131a2.
K. Ali et al., "Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents," New England Journal of Medicine, vol. 385, no. 24, pp. 2241-2251, 2021.
L. Chu et al., "A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine," Vaccine, vol. 39, no. 20, pp. 2791-2799, 2021.
E. B. Walter et al., "Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age," New England Journal of Medicine, vol. 386, no. 1, pp. 35-46, 2022.
R. S. Sablerolles et al., "Immunogenicity and reactogenicity of vaccine boosters after Ad26. COV2. S priming," New England Journal of Medicine, vol. 386, no. 10, pp. 951-963, 2022.
J. Sadoff et al., "Safety and efficacy of single-dose Ad26. COV2. S vaccine against Covid-19," New England Journal of Medicine, vol. 384, no. 23, pp. 2187-2201, 2021.
A. R. Falsey et al., "Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine," New England Journal of Medicine, vol. 385, no. 25, pp. 2348-2360, 2021.
F. P. Polack et al., "Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine," New England journal of medicine, vol. 383, no. 27, pp. 2603-2615, 2020.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 American Scientific Research Journal for Engineering, Technology, and Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors who submit papers with this journal agree to the following terms.
